DKK1 and neoplasm: Ryan et al. [56] showed that DKN-01, a humanized IgG4 monoclonal antibody, enhanced the anti-tumor efficacy of paclitaxel in patients with DKK1-expressing esophageal or gastro-esophageal junction tumors.